Welcome, Guest. Please login or register.
November 20, 2017, 01:38:49 AM

Login with username, password and session length

  • Total Posts: 722494
  • Total Topics: 58711
  • Online Today: 325
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 4
Guests: 302
Total: 306


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New HIV Drug Maraviroc Recommended for Approval  (Read 1855 times)

0 Members and 1 Guest are viewing this topic.

Offline J220

  • Member
  • Posts: 587
New HIV Drug Maraviroc Recommended for Approval
« on: April 24, 2007, 09:36:15 PM »
Good news, looks like it's a step closer for approval.

New HIV Drug Recommended for Approval  
Published: April 24, 2007

WASHINGTON (AP) -- The federal government should approve a novel drug that targets the cells of HIV-infected patients and not the virus itself, health advisers recommended Tuesday.

The 12 advisers unanimously voted to urge the Food and Drug Administration to approve maraviroc, which Pfizer Inc. hopes to sell under the brand name Celsentri. It would represent the first so-called CCR5 receptor antagonist to be sold.

The drugs block a secondary but crucial doorway typically used by the human immunodeficiency virus to enter white blood cells, which are important in the immune system.

The FDA advisers recommended that Pfizer further study Celsentri's interaction with other drugs and its effects on women and minorities. The group's advice is nonbinding, but the FDA generally follows it.

The FDA and Pfizer have cited studies showing that adding Celsentri to a traditional HIV treatment regimen was more effective in dropping the virus below detectable levels. HIV is the virus that causes AIDS.

FDA concerns about the entire class of drugs include the possibility of greater risk of infection, lymphoma or liver damage in HIV patients. The drugs also have been linked to heart rhythm changes in laboratory animals.

FDA reviewers noted no increase in lymphomas or infections among patients given Celsentri, but said there was a modest increase in liver problems.

Pfizer said its analyses of studies of the drug found no significant impact on the heart, and no increased incidence of liver problems, cancer or infection compared with treatment involving other HIV drugs.

Most worrisome is that the drugs could accelerate a shift from one variant of HIV to another, a problem most often seen in the sickest AIDS patients. Patients on Celsentri probably would have to be monitored to determine whether the drug is driving such a shift.

Researchers have known for more than a decade that people who lack a working version of the doorway targeted by the drug -- the CCR5 receptor -- are highly resistant to infection by HIV or slow to develop AIDS once infected.
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

Offline Tim Horn

  • Member
  • Posts: 799


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.